Dolastatin 15

Dolastatin 15 (DLS 15), a depsipeptide derived from Dolabella auricularia, is a potent antimitotic agent structurally related to the antitubulin agent Dolastatin 10. Dolastatin 15 induces cell cycle arrest and apoptosis in multiple myeloma cells. Dolastatin 15 can be used as an ADC cytotoxin[1][2][3].

Product Specifications

CAS Number

[123884-00-4]

Product Name Alternative

DLS 15

UNSPSC

12352209

Target

ADC Payload; Apoptosis; Microtubule/Tubulin

Type

Peptides

Related Pathways

Antibody-drug Conjugate/ADC Related; Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/dolastatin-15.html

Solubility

10 mM in DMSO

Smiles

O=C(N(C1=O)[C@H](C(OC)=C1)CC2=CC=CC=C2)[C@H](C(C)C)OC([C@H](CCC3)N3C([C@H](CCC4)N4C([C@H](C(C)C)N(C)C([C@H](C(C)C)NC([C@@H](N(C)C)C(C)C)=O)=O)=O)=O)=O

Molecular Formula

C45H68N6O9

Molecular Weight

837.06

References & Citations

[1]Bai R, et al. Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules. Biochem Pharmacol. 1992 Jun 23;43 (12) :2637-45.|[2]Sato M, et al. A natural peptide, dolastatin 15, induces G2/M cell cycle arrest and apoptosis of human multiple myeloma cells. Int J Oncol. 2007 Jun;30 (6) :1453-9.|[3]Gianolio DA, et al. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates. Cancer Chemother Pharmacol. 2012 Sep;70 (3) :439-49.|[4]Ali MA, et al. Dolastatin 15 induces apoptosis and BCL-2 phosphorylation in small cell lung cancer cell lines. Anticancer Res. 1998 Mar-Apr;18 (2A) :1021-6.